"目录号: HY-14233
Cytoskeleton-
Omecamtiv mecarbil 是具有选择性的myosin激活剂，常用于治疗心血管疾病。
Myosin
相关产品
(-)-Blebbistatin-ML-7 hydrochloride-BTS-MLCK inhibitor peptide 18-
生物活性
Description
Omecamtiv mecarbil is a selectivemyosinactivator, used for the treatment of cardiovascular diseases.
In Vitro
Omecamtiv mecarbil (10 μM) reduces the maximal ATPase (kcat) 4.5-fold and dramatically reduces the actin concentration at which ATPase is half-maximal (KATPase) 30-fold. The Omecamtiv mecarbil-induced inhibition of the actin-activated ATPase is evaluated in a concentration-dependent manner to determine the EC50(0.52 ± 0.10 μM). Omecamtiv mecarbil does not change the overall actin affinity. Omecamtiv mecarbil traps a population of myosin heads in a weak actin affinity state with slow product release. Omecamtiv mecarbil can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay[3].
In Vivo
Omecamtiv mecarbil (100-1000 ng/mL) demonstrates concentration-dependent increases in FS in Sprague?Dawley rats model. Omecamtiv mecarbil demonstrates good PK parameters in both rats (Sprague?Dawley) and dogs (Beagle) with clearances of 22 and 7.2 mL/min/kg, volumes of 3.5 and 3.6 L/kg, and bioavailabilities (F%) of 100 and 80%, respectively[1]. Omecamtiv mecarbil does not affect the phosphorylation status of myofilament proteins in both WT and KO hearts as shown by the absence of significant differences between pre and post Omecamtiv mecarbil samples within WT and KO groups, or affect the force generation at maximal Ca2+activation (pCa 4.5) in any of the groups. Omecamtiv mecarbil increases the responsiveness of the cardiac myofilaments to Ca2+at submaximal Ca2+-activations[2].
Clinical Trial
NCT00748579
Cytokinetics
Heart Failure
September 2008
Phase 2
NCT00941681
Cytokinetics
Heart Failure
April 2009
Phase 2
NCT00624442
Cytokinetics
Heart Failure
April 2007
Phase 2
NCT00682565
Cytokinetics
Heart Failure-Myocardial Ischemia-Angina Pectoris
April 2008
Phase 2
NCT01077167
Amgen
Heart Failure
July 2010
Phase 2
NCT01300013
Amgen-Cytokinetics
Heart Failure
April 2011
Phase 2
NCT01380223
Cytokinetics
Heart Failure
August 2005
Phase 1
NCT02929329
Amgen-Cytokinetics-Servier
Heart Failure
January 6, 2017
Phase 3
NCT02695420
Amgen
Heart Failure With Reduced Ejection Fraction
April 14, 2016
Phase 2
NCT01786512
Amgen-Cytokinetics
Modified Release Oral Formulation-Left Ventricular Systolic Dysfunction-Chronic Heart Failure-History of Chronic Heart Failure-Left Ventricular Ejection Fraction-Pharmacokinetics-Echocardiogram
February 2013
Phase 2
View MoreCollapse
References
[1].Morgan BP, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett. 2010 Aug 20;1(9):472-7.
[2].Mamidi R, et al. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C. J Mol Cell Cardiol. 2015 Aug;85:262-72.
[3].Swenson AM, et al. Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle. J Biol Chem. 2017 Mar 3;292(9):3768-3778.